Overview
Nuravax Inc, a clinical-stage biopharmaceutical company developing active immunotherapies for neurodegenerative diseases, announced that two oral presentations - the phase 1 clinical results and the phase 2 secondary prevention study design for its licensed lead drug product, the amyloid-beta (Aß) vaccine, AV-1959R - have been accepted at the 18th Clinical Trials on Alzheimer's Disease (CTAD-25) conference, scheduled for December 3–5, 2025 in San Diego, California.
Two oral presentations to highlight the safety, immunogenicity, and future development of AV-1959R for primary and secondary prevention of Alzheimer's disease.
Statement from Roman Kniazev: CEO of Nuravax, Inc.
Roman Kniazev, CEO of Nuravax, Inc., said, ""The MultiTEP platform behind AV-1959R was specifically engineered to overcome immunological tolerance and safely induce strong anti-Aß antibody responses across diverse populations at risk,"" and he continued, ""The phase 1 outcomes may validate decades of translational vaccine research and offer a path forward for active immunization and prevention or mitigation of risk.""
The AV-1959R is an adjuvanted, Aß epitope-specific vaccine built on the proprietary MultiTEP platform, designed to induce high levels of antibodies while avoiding autoreactive T cell responses. It is intended for both secondary prevention in individuals with biomarker-positive disease and primary preventive therapy for individuals at elevated risk of Alzheimer's pathology due to known factors, including a family history of the disease, the presence of the APOE4 genotype, mutations in APP, PSEN1, PSEN2, TREM2, and CASP8 genes as well as comorbid conditions (e.g., hypertension, hyperlipidemia, type 2 diabetes mellitus, obesity, etc).
About the biotechnology compamy: Nuravax
- Nuravax is a clinical-stage biotechnology company developing immunotherapy vaccines for neurodegenerative diseases such as Alzheimer's, disease, Parkinson's disease, TBI, and CTE.
- Focused on early intervention, it leads the clinical, regulatory, and manufacturing efforts for Duvax - a dual-target vaccine licensed from the Institute for Molecular Medicine.
